Since 1989, the United States has pursued a goal of eliminating tuberculosis (TB)
through a strategy of rapidly identifying and treating cases and evaluating exposed
contacts to limit secondary cases resulting from recent TB transmission (
1
). This strategy has been highly effective in reducing U.S. TB incidence (
2
), but the pace of decline has significantly slowed in recent years (2.2% average
annual decline during 2012–2017 compared with 6.7% during 2007–2012) (
3
). For this report, provisional 2019 data reported to CDC’s National Tuberculosis
Surveillance System were analyzed to determine TB incidence overall and for selected
subpopulations and these results were compared with those from previous years. During
2019, a total of 8,920 new cases were provisionally reported in the United States,
representing a 1.1% decrease from 2018.* TB incidence decreased to 2.7 cases per 100,000
persons, a 1.6% decrease from 2018. Non–U.S.-born persons had a TB rate 15.5 times
greater than the rate among U.S.-born persons. The U.S. TB case count and rate are
the lowest ever reported, but the pace of decline remains slow. In recent years, approximately
80% of U.S. TB cases have been attributed to reactivation of latent TB infection (LTBI)
acquired years in the past, often outside the United States (
2
). An expanded TB elimination strategy for this new decade should leverage existing
health care resources, including primary care providers, to identify and treat persons
with LTBI, without diverting public health resources from the continued need to limit
TB transmission within the United States. Partnerships with health care providers,
including private providers, are essential for this strategy’s success.
Health departments in the 50 U.S. states and the District of Columbia (DC) report
all TB cases that meet the Council of State and Territorial Epidemiologists’ surveillance
case definition
†
to CDC. Reports include patient demographics, clinical features, and medical and social
risk factors. Self-reported race/ethnicity data are collected and reported following
federal standards; Hispanics/Latinos can be of any race, and all other reported race
categories are non-Hispanic/Latino. The U.S. Census Bureau defines a U.S.-born person
as one born in the United States or a U.S. territory or born abroad to a U.S. citizen
parent. Rates (cases per 100,000 persons) were calculated for the United States and
administrative divisions (i.e., the 50 states, DC, and census divisions) using midyear
U.S. Census Bureau population estimates.
§
Rates by national origin and race/ethnicity were calculated using midyear Current
Population Survey estimates.
¶
Average annual percentage changes (APC) in incidence were calculated for 2007–2012
and 2012–2019; these years were selected based on previous research demonstrating
a statistically significant change in incidence trends during 2007 and 2012 (
3
). Data regarding drug-resistant TB cases are reported for 2018, the most recent year
for which complete drug-resistance data are available.
U.S. TB incidence decreased an average of 2.1% per year during 2012–2019, a slower
rate of decline than the average 6.4% per year during 2007–2012. The overall U.S.
TB rate for 2019 was 2.7 cases per 100,000 persons, while state-specific 2019 TB rates
ranged from 0.2 (Wyoming) to 8.1 (Alaska) (Table 1). Nine states (Alaska, California,
Georgia, Hawaii, Maryland, New Jersey, New York, Texas, and Washington) and DC reported
TB rates higher than the national rate. Four states (California, Florida, New York,
and Texas) continued to account for approximately half of all reported TB cases.
TABLE 1
Tuberculosis (TB) case counts and rates with annual percentage changes, by U.S. Census
division and state or district — United States, 2018 and 2019
Census division/State
No. of reported TB cases*
TB rate†
2018
2019
% change
2018
2019
% change§
Division 1: New England
Connecticut
51
67
31.4
1.4
1.9
31.6
Maine
14
19
35.7
1.0
1.4
35.2
Massachusetts
200
179
–10.5
2.9
2.6
–10.6
New Hampshire
12
6
–50.0
0.9
0.4
–50.2
Rhode Island
20
14
–30.0
1.9
1.3
–30.1
Vermont
5
3
–40.0
0.8
0.5
–40.0
Subtotal
302
288
–4.6
2.0
1.9
–4.7
Division 2: Middle Atlantic
New Jersey
291
311
6.9
3.3
3.5
6.9
New York
744
754
1.3
3.8
3.9
1.7
Pennsylvania
213
198
–7.0
1.7
1.5
–7.1
Subtotal
1,248
1,263
1.2
3.0
3.1
1.4
Division 3: East North Central
Illinois
319
327
2.5
2.5
2.6
2.9
Indiana
116
108
–6.9
1.7
1.6
–7.4
Michigan
108
132
22.2
1.1
1.3
22.2
Ohio
178
150
–15.7
1.5
1.3
–15.8
Wisconsin
49
51
4.1
0.8
0.9
3.8
Subtotal
770
768
–0.3
1.6
1.6
–0.3
Division 4: West North Central
Iowa
49
52
6.1
1.6
1.6
5.9
Kansas
28
38
35.7
1.0
1.3
35.6
Minnesota
172
147
–14.5
3.1
2.6
–15.0
Missouri
80
70
–12.5
1.3
1.1
–12.7
Nebraska
27
17
–37.0
1.4
0.9
–37.3
North Dakota
13
18
38.5
1.7
2.4
37.7
South Dakota
12
16
33.3
1.4
1.8
32.4
Subtotal
381
358
–6.0
1.8
1.7
–6.4
Division 5: South Atlantic
Delaware
22
19
–13.6
2.3
2.0
–14.4
District of Columbia
36
24
–33.3
5.1
3.4
–33.7
Florida
591
558
–5.6
2.8
2.6
–6.6
Georgia
271
301
11.1
2.6
2.8
10.0
Maryland
210
212
1.0
3.5
3.5
0.8
North Carolina
196
185
–5.6
1.9
1.8
–6.6
South Carolina
86
80
–7.0
1.7
1.6
–8.1
Virginia
205
190
–7.3
2.4
2.2
–7.7
West Virginia
6
10
66.7
0.3
0.6
67.8
Subtotal
1,623
1,579
–2.7
2.5
2.4
–3.5
Division 6: East South Central
Alabama
91
87
–4.4
1.9
1.8
–4.7
Kentucky
65
66
1.5
1.5
1.5
1.4
Mississippi
81
58
–28.4
2.7
1.9
–28.3
Tennessee
139
128
–7.9
2.1
1.9
–8.7
Subtotal
376
339
–9.8
2.0
1.8
–10.2
Division 7: West South Central
Arkansas
76
63
–17.1
2.5
2.1
–17.3
Louisiana
105
89
–15.2
2.3
1.9
–15.0
Oklahoma
74
72
–2.7
1.9
1.8
–3.1
Texas
1,124
1,153
2.6
3.9
4.0
1.3
Subtotal
1,379
1,377
–0.1
3.4
3.4
–1.1
Division 8: Mountain
Arizona
178
184
3.4
2.5
2.5
1.7
Colorado
64
66
3.1
1.1
1.1
1.9
Idaho
15
7
–53.3
0.9
0.4
–54.3
Montana
5
2
–60.0
0.5
0.2
–60.3
Nevada
69
52
–24.6
2.3
1.7
–25.9
New Mexico
41
40
–2.4
2.0
1.9
–2.6
Utah
18
27
50.0
0.6
0.8
47.5
Wyoming
1
1
0.0
0.2
0.2
–0.2
Subtotal
391
379
–3.1
1.6
1.5
–4.4
Division 9: Pacific
Alaska
63
59
–6.3
8.6
8.1
–5.9
California
2,097
2,118
1.0
5.3
5.4
0.9
Hawaii
120
99
–17.5
8.4
7.0
–17.2
Oregon
81
70
–13.6
1.9
1.7
–14.3
Washington
190
223
17.4
2.5
2.9
16.0
Subtotal
2,551
2,569
0.7
4.8
4.8
0.4
Total
9,021
8,920
–1.1
2.8
2.7
–1.6
* Based on data from the National Tuberculosis Surveillance System as of March 3,
2020.
† Cases per 100,000 persons. Calculated using midyear population estimates from the
U.S. Census Bureau.
§ Calculated using unrounded figures.
Among 8,920 TB cases reported during 2019, a total of 6,322 (70.9%) occurred among
non–U.S.-born persons (Table 2). From 2018 to 2019, the rate among U.S.-born persons
declined 4.2% (to 0.9 cases per 100,000 persons), while the rate among non–U.S.-born
persons declined 1.5% (to 14.1) (Table 2) (Figure).
TABLE 2
Tuberculosis (TB) case counts and rates, by national origin and race/ethnicity — United
States, 2016–2019
U.S. population group
No. of cases* (rate†)
2016
2017
2018
2019
U.S.-born§ persons
Hispanic/Latino
593 (1.6)
582 (1.5)
589 (1.5)
628 (1.6)
White
904 (0.5)
790 (0.4)
807 (0.4)
756 (0.4)
Black/African American
1,057 (3.0)
999 (2.8)
950 (2.7)
905 (2.5)
Asian
144 (2.1)
134 (1.9)
137 (1.9)
120 (1.6)
American Indian/Alaska Native
110 (5.1)
91 (3.8)
102 (4.0)
79 (3.4)
Native Hawaiian/Pacific Islander
30 (4.1)
45 (6.5)
42 (5.6)
23 (3.5)
Multiple or unknown race/ethnicity
22 (—¶)
28 (—¶)
31 (—¶)
42 (—¶)
Subtotal
2,860 (1.0)
2,669 (1.0)
2,658 (1.0)
2,553 (0.9)
Non–U.S.-born persons
Hispanic/Latino
1,976 (10.0)
1,959 (9.9)
2,039 (10.3)
2,065 (10.2)
White
281 (3.7)
266 (3.4)
261 (3.2)
250 (3.1)
Black/African American
911 (22.7)
899 (22.2)
846 (20.3)
825 (19.5)
Asian
3,055 (27.2)
3,128 (27.3)
3,069 (26.0)
3,000 (25.7)
American Indian/Alaska Native
1 (2.9)
2 (2.9)
2 (3.5)
3 (5.3)
Native Hawaiian/Pacific Islander
46 (12.7)
67 (22.7)
72 (24.4)
81 (25.1)
Multiple or unknown race/ethnicity
64 (—¶)
52 (—¶)
70 (—¶)
98 (—¶)
Subtotal
6,334 (14.7)
6,373 (14.7)
6,359 (14.3)
6,322 (14.1)
Unknown national origin
5 (—¶)
7 (—¶)
4 (—¶)
45 (—¶)
Total
9,199 (2.8)
9,049 (2.8)
9,021 (2.8)
8,920 (2.7)
* Based on data from the National Tuberculosis Surveillance System as of March 3,
2020.
† Cases per 100,000 persons. Rates according to national origin and race/ethnicity
were calculated using midyear population estimates from the Current Population Survey.
Total rate was calculated using midyear population estimates from the U.S. Census
Bureau.
§ U.S.-born persons were those born in the United States or U.S. territories (American
Samoa, Northern Mariana Islands, Guam, Puerto Rico, or U.S. Virgin Islands) or born
elsewhere to a U.S. citizen. Non–U.S.-born persons were born outside the United States
and U.S. territories, and include those born in the sovereign freely associated states
(Federated States of Micronesia, Marshall Islands, or Palau) unless one or both parents
were U.S. citizens.
¶ Rates could not be calculated for these categories because population estimates
are not available.
FIGURE
Tuberculosis (TB) case counts and rates, by national origin*
,†
— United States, 2007–2019
* Number of cases with unknown national origin not shown (range = 2–60 per year; median
= 7). Total rate includes cases with unknown national origin.
†
Rates for non–U.S.-born and U.S.-born persons were calculated using Current Population
Survey estimates. Total rate was calculated using U.S. Census Bureau population estimates.
The figure is a histogram showing the number of TB cases and TB rates, by national
origin, among persons in the United States during 2007–2019.
Among non–U.S.-born persons residing in the United States, TB rates during 2019 were
highest among Asians (25.7 per 100,000), followed by Native Hawaiians/Pacific Islanders
(25.1), blacks/African Americans (19.5), Hispanics/Latinos (10.2), and American Indians/Alaska
Natives (5.3) and were lowest among whites (3.1) (Table 2). Rates decreased from 2018
to 2019 for all non–U.S.-born groups except American Indians/Alaska Natives and Native
Hawaiians/Pacific Islanders. The top five countries of birth among non–U.S.-born persons
with incident TB in 2019 were Mexico (1,165 cases; 18.4% of non–U.S.-born cases),
the Philippines (790; 12.5%), India (573; 9.1%), Vietnam (503; 8.0%), and China (387;
6.1%).
Among U.S.-born persons, 2019 rates were highest for Native Hawaiians/Pacific Islanders
(3.5), followed by American Indians/Alaska Natives (3.4), blacks/African Americans
(2.5), Hispanics/Latinos (1.6), and Asians (1.6) and were lowest among whites (0.4).
TB incidence decreased from 2018 to 2019 for all U.S.-born groups except Hispanics.
Human immunodeficiency virus (HIV) status was known for 87.3% of reported 2019 TB
cases; 4.9% of those patients were coinfected with HIV, including 7.8% of persons
aged 25–44 years. Initial drug-susceptibility testing results for at least isoniazid
and rifampin were reported for 94.9% of culture-confirmed cases during 2018, the most
recent year for which complete data are available.** Among the 6,746 cases during
2018 with available drug-susceptibility test data, 102 (1.5%) were multidrug-resistant
††
; 88 (86.3%) of these cases were among non–U.S.-born persons; 83 (81.4%) reported
no previous TB episode. One case of extensively drug-resistant TB
§§
was reported during 2018; this case occurred in a non–U.S.-born person with a reported
previous episode of TB disease.
Discussion
Since adoption of the U.S. TB elimination strategy in 1989 (
1
), TB incidence has decreased by approximately two thirds (
2
), demonstrating the effectiveness of efforts during the last three decades to prevent
TB transmission in the United States. However, the pace of progress has slowed since
2012 (
3
). This slowing is primarily related to the declining proportion of TB cases caused
by recent transmission within the United States, against which the U.S. TB elimination
strategy has been most effective (
4
). Currently, approximately 80% of TB cases result from reactivation of LTBI acquired
years in the past, often outside the United States (
2
).
This shift in U.S. TB epidemiology from being driven primarily by recent transmission
within the United States to reactivation of LTBI acquired in the past (often outside
the United States) requires an expanded strategy that increases emphasis on detecting
and treating LTBI. However, this expanded focus on LTBI cannot compromise existing
efforts to prevent TB transmission if the United States is to avoid another TB resurgence,
as occurred in the late 1980s and early 1990s (
5
). The U.S. Preventive Services Task Force and CDC recommend routine LTBI screening
for populations at increased risk, including persons who have lived in countries with
increased TB prevalence and persons who have resided in high-risk congregate settings
(e.g., homeless shelters or correctional facilities) (
6
). The efficacy and cost-effectiveness of LTBI screening and treatment, when implemented
in populations at risk, compare favorably with other widely accepted preventive care
interventions, including mammography to screen for breast cancer (
7
) and use of statins to prevent cardiovascular disease (
8
). LTBI screening (and treatment as indicated) should therefore be considered a routine
and integral part of primary care for patients at elevated risk for LTBI.
The findings in this report are subject to at least four limitations. First, this
analysis is based on provisional case counts for 2019; however, in previous years,
final case counts and rates have not differed greatly from the provisional figures.
Second, rates were calculated using estimated population denominators; as a result,
rates might change slightly as population estimates are refined in the future. Third,
incidence trends for some demographic groups with few patients, e.g., non–U.S.-born
American Indian/Alaska Natives, should be interpreted cautiously because of the increased
volatility in these rates. Finally, complete drug susceptibility test data are not
available for 2019 because susceptibility testing might take several weeks to complete
because of the slow-growing nature of Mycobacterium tuberculosis.
Concerns regarding the potential adverse effects of LTBI treatment have been an important
barrier to LTBI screening and treatment in the past (
9
). To address these concerns, CDC and the National Tuberculosis Controllers Association
have released new guidelines that recommend short-course, rifamycin-based regimens,
which have less toxicity and better completion rates than does isoniazid monotherapy
(
10
). CDC will continue to support and encourage public health partners and primary care
providers to increase adoption of LTBI testing and treatment guidelines to accelerate
progress toward TB elimination.
Summary
What is already known about this topic?
Tuberculosis (TB) incidence in the United States has steadily declined since 1993,
but the pace of decline has slowed in recent years.
What is added by this report?
The U.S. TB rate during 2019 declined to 2.7 cases per 100,000 persons, the lowest
level on record. However, the annual pace of decline (−1.6% from 2018) remains slow,
particularly among TB cases that are attributed to reactivation of latent TB infection
(LTBI).
What are the implications for public health practice?
To eliminate TB, the United States needs to expand testing and treatment for LTBI
while continuing to prevent TB transmission. Partnerships with health care providers,
including private providers, are essential for this strategy’s success.